Prestige Consumer Healthcare (PBH)
NYSEHealth CareMedical - PharmaceuticalsSnapshot 2026-11-05
$44.32-16.82%
Close 2026-11-05 · 1-day change
NYSEHealth CareMedical - PharmaceuticalsSnapshot 2026-11-05
QuarterlyIQ Insights · PBH
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance is holding in the top half of its industry — the reason to own it looks intact.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | -22.4% |
| Our one-year growth estimate | diamond | 12.9% |
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
No outside relationship met the current evidence threshold.
Based on historical daily prices through 2026-11-05.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
A larger daily loss that occurred about once in every 20 trading days.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Growth built into the price is above our model estimate.
The price assumes 35.3 percentage points less one-year growth.
The one-year revenue growth assumption on Valuation.
Worth watching into the next print: this name its industry peers have been missing lately and operates in a high-miss-rate industry. A fundamental tilt, not a price call.
Model as of 2026-11-05 · Compared with 3 industry peers · Company calendar date is not available
PBH — President transition
Dated 2026-08-14
Senior Vice President, Operations — Jeffrey Zerillo: The executive is retiring from a senior operational role, which constitutes an orderly succession rather than a sudden loss or shock departure.
Why it matters: Strong cash flow can help PBH pay down debt after its deals. Q1 cash flow also rose due to working capital timing.
Supportive ifFiscal 2027 adjusted free cash flow reaches at least $270 million.
Worry ifFiscal 2027 adjusted free cash flow falls below $250 million.
Why it matters: Limited Clear Eyes supply hurt fiscal 2026 sales. Management says output is rising, but supply remains variable.
Supportive ifThe next report says Clear Eyes supply met demand, and Eye & Ear Care sales rose year over year.
Worry ifThe next report again cites limited Clear Eyes supply, and Eye & Ear Care sales fall year over year.
Why it matters: The two deals raised fiscal 2027 revenue guidance. Their sales growth will show whether the new brands add momentum.
Supportive ifA quarterly report shows sales rose for both acquired brands. LaCorium also reports year-over-year growth.
Worry ifA quarterly report shows either acquired brand had lower sales than a year earlier.
We watch for confirming and disproving signals on each item. Resolutions are found automatically where possible and checked by hand for unclear cases. Last 90 days shown.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$148 on $10,000 · ±1.5% | How much price usually moves either way. |
| Bad day | $342 loss on $10,000 · 3.4% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $3,688 loss on $10,000 · 36.9% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.